Back to Search Start Over

The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer

Authors :
Ashika D. Maharaj
Brett Knowles
Katherine M. White
Marty Smith
Neil D. Merrett
David Goldstein
Jeremy Shapiro
Susan E. Evans
Theresa M. Hayes
Nezor Houli
Daniel Croagh
John Spillane
Rachel Wong
Rachel E. Neale
Jennifer Philip
Mehrdad Nikfarjam
J. Holland
Liane Ioannou
Maddy Quinn
Elizabeth Burmeister
John Zalcberg
Arul Earnest
Trevor Leong
Peter Evans
James G. Kench
Charles H.C. Pilgrim
Source :
HPB : the official journal of the International Hepato Pancreato Biliary Association. 24(6)
Publication Year :
2021

Abstract

Background Pancreatic cancer (PC) remains a highly fatal disease. There is a gap in the literature on the of quality care on survival in a real-world population. Objectives This study: (1) assessed compliance with a consensus set of quality indicators (QIs); and (2) evaluated the association between compliance with these QIs and survival. Methods Data were collected on a core set of quality indicators by the Upper Gastrointestinal Cancer Registry (UGICR) for patients diagnosed with PC between 1 January 2016 and 31 December 2019. Univariable and multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for the association between survival and patient characteristics, hospital characteristics and QIs, stratified by resectability. A multivariable analysis tested the relationship between significant patient and hospital characteristics, patient cluster effects within hospitals and survival. Results 1061 patients were eligible for this study with 52% male, 71% over the age of 65, 23% potentially resectable and 51% with metastatic disease at diagnosis. 52% received some form of cancer directed treatment. Significant association with improved survival were: (1) in the potentially resectable group having adjuvant chemotherapy administered following surgery or a reason documented (HR, 0.29; 95 CI, 0.19-0.46); (2) in the locally advanced group included having chemotherapy ± chemoradiation, or a reason documented for not undergoing treatment (HR, 0.38; 95 CI, 0.25-0.58) and (3) in the metastatic disease group included having documented ECOG at presentation and/or American society of Anaesthesiologists (ASA) performance status at a diagnostic procedure (HR, 0.65; 95 CI, 0.47-0.89), being seen by a medical oncologist and/or a radiation oncologist in the absence of treatment (HR, 0.48; 95 CI, 0.31-0.77), and having disease management discussed at an MDT meeting (HR, 0.79; 95 CI, 0.64-0.96). Conclusion Capture of a concise data set has enabled quality of care to be assessed and an analysis of factors associated with improved survival identified.

Details

ISSN :
14772574
Volume :
24
Issue :
6
Database :
OpenAIRE
Journal :
HPB : the official journal of the International Hepato Pancreato Biliary Association
Accession number :
edsair.doi.dedup.....3a0d8fb087da00c5ed7059feb7f7f2f5